icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Substantial
Substantial in the treatment of SJIA.
Clinical Added Value
moderate
Like ROACTEMRA (tocilizumab), ILARIS (canakinumab) provides a moderate improvement in actual benefit (level III) in the management of patients aged 2 years and older, with active systemic juvenile idiopathic arthritis, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids.
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
Wh9BYXKuQs5SGsxz